Download

Disease/health condition - Hepatitis B virus (HBV) infection
Hepatitis B e antigen (HBeAg)
Setting:
2. Laboratory
Tiered Testing Service:
District hospital with laboratory
Assay format
Lateral flow RDT
Information History
First added in 2018
Changed in 2024
Purpose type
Staging, Treatment selection
Purpose
Staging to assess the need for HBV treatment in chronic HBV infection together with ALT measurement, and as a criterion for use of antivirals in pregnant women to prevent mother-to-child transmission.* .
* This test should be used only when HBV DNA testing is not available
Specimen types
Serum, Plasma
WHO prequalified or recommended products
N/A
GMDN

48332

Hepatitis B virus e-antigen IVD, kit, rapid ICT, clinical

A collection of reagents and other associated materials intended to be used for the qualitative and/or (semi-)quantitative detection of Hepatitis B virus e-antigen in a clinical specimen within a short period, relative to standard laboratory testing procedures, using an immunochromatographic test (ICT) method* . This is a rapid test used in the laboratory or in point-of-care analyses. It is not intended to be used for self-testing.

The medical device term(s), code(s) and definition(s) in this section were retrieved from databases external to WHO. As there might be more than one name, definition and “Nomenclature Code” related to the specific medical device, please consult https://gmdnagency.org GMDN ®. © GMDN Agency 2005-2024
* lateral flow test
EMDN

W0105090299

HEPATITIS VIRUSES - RT & POC - OTHER

The code(s) and term(s) in this section were observed and retrieved from public databases and have not been validated by health regulatory authorities. Please consult your regulatory agency and EMDN site: https://webgate.ec.europa.eu/dyna2/emdn
WHO supporting publications
World Health Organization. (‎2017)‎. WHO guidelines on hepatitis B and C testing. World Health Organization. https://iris.who.int/handle/10665/254621 ; World Health Organization. (‎2024)‎. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization. https://iris.who.int/handle/10665/376353
Technical specifications
N/A
SAGE IVD recommended including this test in the EDL on the basis of the scientific validity of the analyte and the availability of WHO guidelines and technical reports, including recommendations for the use of this test. The selection of disease specific tests for the EDL also took into account relevant priority diseases for WHO such as NCDs including DM, CVD and cancer, HIV infection, malaria, NTDs, STIs, tuberculosis, viral hepatitis B and C, among others.
N/A
The inclusion of this test was based on WHO guidelines and/or technical documents that include recommendations for the use of this test.
N/A